{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:15:58Z","timestamp":1778728558416,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.therap.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T02:24:28Z","timestamp":1676427868000},"page":"647-657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020"],"prefix":"10.1016","volume":"78","author":[{"given":"Laurine","family":"Diaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Jouanjus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Fouilh\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Djezzar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Gibaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reynald","family":"Le Boisselier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Libert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sylvie","family":"Caous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Monzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryl\u00e8ne","family":"Guerlais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Fauconneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Peyri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.02.002_bib0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.therap.2023.02.002_bib0235","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-199324060-00003","article-title":"Clinical pharmacokinetics of alprazolam","volume":"24","author":"Greenblatt","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2023.02.002_bib0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00003495-199448010-00004","article-title":"Guidelines for the rational use of benzodiazepines: when and what to use","volume":"48","author":"Ashton","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.therap.2023.02.002_bib0245","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/bcp.14537","article-title":"Non-medical use of benzodiazepines and GABA analogues in Europe","volume":"87","author":"Hockenhull","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.02.002_bib0250","series-title":"StatPearls [Internet]","article-title":"Alprazolam","author":"George","year":"2022"},{"key":"10.1016\/j.therap.2023.02.002_bib0255","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18773\/austprescr.2015.055","article-title":"Management of benzodiazepine misuse and dependence","volume":"38","author":"Brett","year":"2015","journal-title":"Aust Prescr"},{"key":"10.1016\/j.therap.2023.02.002_bib0260","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2125.2004.02089.x","article-title":"Whyte. Alprazolam is relatively more toxic than other benzodiazepines in overdose","volume":"58","author":"Isbister","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.02.002_bib0265","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.therap.2020.06.006","article-title":"Addictovigilance contribution during COVID-19 epidemic and lockdown in France","volume":"75","author":"Lapeyre-Mestre","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.02.002_bib0270","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.02.002_bib0275","series-title":"Addictovigilance: surveiller \u00e9valuer et pr\u00e9venir le risque des substances psychoactives \u00e0 potentiel d\u2019abus","year":"2023"},{"key":"10.1016\/j.therap.2023.02.002_bib0280","series-title":"Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4) EMA\/876333\/2011 Rev 4","author":"MA","year":"2017"},{"key":"10.1016\/j.therap.2023.02.002_bib0285","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2017.01.010","article-title":"Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance Network","volume":"72","author":"Frauger","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.02.002_bib0290","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/fcp.12356","article-title":"French Addictovigilance Network. Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion","volume":"32","author":"Jouanjus","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.02.002_bib0295","first-page":"416","article-title":"Drames (D\u00e9c\u00e8s en relation avec l\u2019abus de m\u00e9dicaments et de substances): outil d\u2019identification des d\u00e9c\u00e8s li\u00e9s \u00e0 la drogues en France","volume":"40\u201341","author":"Richard","year":"2010","journal-title":"BEH"},{"key":"10.1016\/j.therap.2023.02.002_bib0300","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00414-008-0291-x","article-title":"French Network of Centers for Evaluation and Information on Pharmacodependence. Chemical submission: results of 4-year French inquiry","volume":"123","author":"Djezzar","year":"2009","journal-title":"Int J Legal Med"},{"key":"10.1016\/j.therap.2023.02.002_bib0305","series-title":"Uppsala Monitoring Centre","author":"VigiBase","year":"2023"},{"key":"10.1016\/j.therap.2023.02.002_bib0310","series-title":"Medical Dictionary for Regulatory Activity. Welcome to MedDRA | MedDRA","year":"2023"},{"key":"10.1016\/j.therap.2023.02.002_bib0315","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","article-title":"Les \u00e9tudes cas\u2013non cas: principe, m\u00e9thodes, biais et interpr\u00e9tations","volume":"73","author":"Faillie","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.02.002_bib0320","unstructured":"Open Medic: base compl\u00e8te sur les d\u00e9penses de m\u00e9dicaments en 2020 | L\u2019Assurance Maladie. https:\/\/assurance-maladie.ameli.fr\/etudes-et-donnees\/open-medic-base-complete-depenses-medicaments-2020.[Accessed 9 February 2023]."},{"key":"10.1016\/j.therap.2023.02.002_bib0325","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addbeh.2018.06.013","article-title":"Prescription tranquilizer\/sedative misuse prevalence and correlates across age cohorts in the US","volume":"87","author":"Schepis","year":"2018","journal-title":"Addict Behav"},{"key":"10.1016\/j.therap.2023.02.002_bib0330","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/bcp.13959","article-title":"Nonmedical use of alprazolam in the UK: Results from a nationally representative survey","volume":"85","author":"Hockenhull","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.02.002_bib0335","series-title":"Alcohol and drug treatment for young people: statistics summary 2017 to 2018","author":"GOV UK","year":"2018"},{"key":"10.1016\/j.therap.2023.02.002_bib0340","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/15563650.2019.1674321","article-title":"Child and adolescent benzodiazepine exposure and overdose in the United States: 16 years of poison center data","volume":"58","author":"Friedrich","year":"2020","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.therap.2023.02.002_bib0345","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1749-6632.2010.05894.x","article-title":"Individual vulnerability to addiction","volume":"121","author":"Swendsen","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.therap.2023.02.002_bib0350","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-244X-11-90","article-title":"Benzodiazepine use and misuse among patients in a methadone program","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.therap.2023.02.002_bib0355","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2023.02.002_bib0360","first-page":"364","article-title":"Relative abuse liability of benzodiazepines in methadone maintained populations in three cities","volume":"95","author":"Iguchi","year":"1989","journal-title":"NIDA Res Monograph"},{"key":"10.1016\/j.therap.2023.02.002_bib0365","first-page":"376","article-title":"Sedative\/tranquilizer use and abuse in alcoholics currently in outpatient treatment: incidence, pattern and preference","volume":"95","author":"Wolf","year":"1989","journal-title":"NIDA Res Monograph"},{"key":"10.1016\/j.therap.2023.02.002_bib0370","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2016.06.008","article-title":"Reasons for benzodiazepine use among persons seeking opioid detoxification","volume":"68","author":"Stein","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.therap.2023.02.002_bib0375","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drugpo.2017.07.012","article-title":"\u2018I love having benzos after my coke shot\u2019: The use of psychotropic medication among cocaine users in downtown Montreal","volume":"49","author":"Motta-Ochoa","year":"2017","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2023.02.002_bib0380","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4081\/jphr.2012.e6","article-title":"Misuse of prescription and illicit drugs among high-risk young adults in Los Angeles and New York","volume":"1","author":"Lankenau","year":"2012","journal-title":"J Public Health Res"},{"key":"10.1016\/j.therap.2023.02.002_bib0385","doi-asserted-by":"crossref","first-page":"640120","DOI":"10.3389\/fpsyt.2021.640120","article-title":"Early Detection of prescription drug abuse using doctor shopping monitoring from claims databases: illustration from the experience of the French Addictovigilance Network","volume":"12","author":"Soeiro","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2023.02.002_bib0390","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/bmj.39140.394410.DB","article-title":"Misuse of prescription drugs could soon exceed that of illicit narcotics. UN panel warns","volume":"334","author":"Zarocostas","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.02.002_bib0395","first-page":"1258","article-title":"The ecology of prescription opioid abuse in the USA: geographic variation in patients\u2019 use of multiple prescribers (\u2018doctor shopping\u2019). Pharmacoepidemiol","volume":"23","author":"McDonald","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2023.02.002_bib0400","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5694\/j.1326-5377.2004.tb05887.x","article-title":"Seeking drugs or seeking help? Escalating \u2018doctor shopping\u2019 by young heroin users before fatal overdose","volume":"180","author":"Martyres","year":"2004","journal-title":"Med J Aust"},{"key":"10.1016\/j.therap.2023.02.002_bib0405","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/clpt.2010.154","article-title":"Prescription drug abuse: insight into the epidemic","volume":"88","author":"Hernandez","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.02.002_bib0410","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/ADM.0000000000000350","article-title":"A review of alprazolam use, misuse, and withdrawal","volume":"12","author":"Ait-Daoud","year":"2018","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2023.02.002_bib0415","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0924-977X(00)00137-1","article-title":"Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam","volume":"11","author":"Bentu\u00e9-Ferrer","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2023.02.002_bib0420","first-page":"85","article-title":"Cohort study of the impact of high-dose opioid analgesics on overdose mortality","volume":"17","author":"Dasgupta","year":"2016","journal-title":"Pain Med"},{"key":"10.1016\/j.therap.2023.02.002_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study","volume":"350","author":"Park","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.02.002_bib0430","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amepre.2016.02.014","article-title":"Trends in the concomitant prescribing of opioids and benzodiazepines, 2002\u22122014","volume":"51","author":"Hwang","year":"2016","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.therap.2023.02.002_bib0435","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/bmj.j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.02.002_bib0440","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(21)01653-6","article-title":"A time of crisis for the opioid epidemic in the USA","volume":"398","author":"The Lancet","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.02.002_bib0445","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.therap.2023.02.002_bib0450","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.euroneuro.2015.07.006","article-title":"Benzodiazepines and risk of death: Results from two large cohort studies in France and UK","volume":"25","author":"Palmaro","year":"2015","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:56:56Z","timestamp":1758567416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723000306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0040595723000306"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.02.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}